CURE’s leukemia page is a go-to resource for oncology news and updates in the world of leukemia Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in leukemia.
June 14th 2024
The FDA approved Blincyto for patients aged one month and older with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Blincyto FDA Approved for Pediatric Acute Lymphoblastic Leukemia
September 2nd 2016The FDA has approved Blincyto (blinatumomab) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).